Genovis AB (publ.) Toekomstige groei

Future criteriumcontroles 4/6

Genovis AB (publ.) zal naar verwachting groeien in winst en omzet met respectievelijk 29.3% en 14.6% per jaar. De winst per aandeel zal naar verwachting groeien met 31.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 14.6% zijn.

Belangrijke informatie

29.3%

Groei van de winst

31.6%

Groei van de winst per aandeel

Life Sciences winstgroei	49.7%
Inkomstengroei	14.6%
Toekomstig rendement op eigen vermogen	14.6%
Dekking van analisten	Low
Laatst bijgewerkt	10 Oct 2024

Recente toekomstige groei-updates

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Aug 23

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Recent updates

Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 19

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

Aug 28

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Aug 23

The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Aug 21

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Apr 26

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Mar 18

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

Feb 28

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Feb 22

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Feb 20

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Feb 04

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Oct 06

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Jun 22

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

May 13

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Dec 22

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Nov 14

If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity

Jul 08

Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?

Jun 01

Genovis AB (publ.)'s (STO:GENO) Popularity With Investors Under Threat As Stock Sinks 27%

May 10

One Analyst Just Shaved Their Genovis AB (publ.) (STO:GENO) Forecasts Dramatically

Feb 10

Is Now The Time To Put Genovis AB (publ.) (STO:GENO) On Your Watchlist?

Aug 09

What Is Genovis AB (publ.)'s (STO:GENO) Share Price Doing?

Mar 27

Winst- en omzetgroeiprognoses

OM:GENO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	179	40	36	50	3
12/31/2025	148	35	26	32	3
12/31/2024	127	27	52	51	3
6/30/2024	128	17	27	37	N/A
3/31/2024	128	31	27	39	N/A
12/31/2023	159	62	55	68	N/A
9/30/2023	158	54	40	53	N/A
6/30/2023	151	57	40	49	N/A
3/31/2023	142	42	42	47	N/A
12/31/2022	104	11	-5	-1	N/A
9/30/2022	119	41	40	43	N/A
6/30/2022	112	36	40	43	N/A
3/31/2022	111	36	37	41	N/A
12/31/2021	94	25	41	46	N/A
9/30/2021	71	11	3	6	N/A
6/30/2021	69	12	1	7	N/A
3/31/2021	65	9	-12	9	N/A
12/31/2020	61	6	-17	4	N/A
9/30/2020	54	-3	-16	7	N/A
6/30/2020	64	3	-11	9	N/A
3/31/2020	60	6	4	9	N/A
12/31/2019	61	10	8	13	N/A
9/30/2019	58	12	7	10	N/A
6/30/2019	43	5	0	4	N/A
3/31/2019	40	1	2	3	N/A
12/31/2018	35	-2	-3	-1	N/A
9/30/2018	31	-4	-4	-2	N/A
6/30/2018	27	-6	-6	-5	N/A
3/31/2018	24	-7	N/A	-9	N/A
12/31/2017	23	-8	N/A	-8	N/A
9/30/2017	21	-9	N/A	-9	N/A
6/30/2017	21	-9	N/A	-11	N/A
3/31/2017	20	-14	N/A	-15	N/A
12/31/2016	19	-15	N/A	-16	N/A
9/30/2016	17	-16	N/A	-18	N/A
6/30/2016	16	-21	N/A	-18	N/A
3/31/2016	14	-18	N/A	-14	N/A
12/31/2015	14	-20	N/A	-16	N/A
9/30/2015	13	-25	N/A	-18	N/A
6/30/2015	11	-24	N/A	-20	N/A
3/31/2015	10	-23	N/A	-21	N/A
12/31/2014	10	-22	N/A	-22	N/A
9/30/2014	8	-20	N/A	-18	N/A
6/30/2014	10	-17	N/A	-17	N/A
3/31/2014	11	-16	N/A	-14	N/A
12/31/2013	10	-16	N/A	-12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei GENO ( 29.3% per jaar) ligt boven de spaarquote ( 1.2% ).

Winst versus markt: De winst van GENO ( 29.3% per jaar) zal naar verwachting sneller groeien dan de Swedish markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van GENO zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van GENO ( 14.6% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.04% per jaar).

Hoge groei-inkomsten: De omzet van GENO ( 14.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen GENO zal naar verwachting over 3 jaar laag zijn ( 14.6 %).

Genovis AB (publ.) Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 17% to kr43.00

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Consensus revenue estimates decrease by 13%

Consensus EPS estimates increase by 17%, revenue downgraded

Consensus revenue estimates fall by 11%

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Independent Director recently bought kr148k worth of stock

Genovis AB Launches Fabricator® Xtra

Genovis AB (publ.)'s (STO:GENO) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO).

Leinco Technologies, Inc. acquired QED Bioscience Inc from Genovis AB (publ.) (OM:GENO).

Genovis AB (publ.)'s (STO:GENO) Conservative Accounting Might Explain Soft Earnings

President & CEO recently bought kr311k worth of stock

Price target decreased by 17% to kr43.00

Earnings Miss: Genovis AB (publ.) Missed EPS By 71% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

The Genovis AB (publ.) (STO:GENO) Analysts Have Been Trimming Their Sales Forecasts

Consensus revenue estimates decrease by 13%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Consensus EPS estimates increase by 17%, revenue downgraded

Investor sentiment deteriorates as stock falls 18%

Genovis AB (publ.)'s (STO:GENO) 36% Jump Shows Its Popularity With Investors

Consensus revenue estimates fall by 11%

This Is Why Genovis AB (publ.)'s (STO:GENO) CEO Compensation Looks Appropriate

Genovis AB (publ.) Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 19%

Is Now The Time To Look At Buying Genovis AB (publ.) (STO:GENO)?

Investor sentiment deteriorates as stock falls 17%

Price target decreased by 16% to kr61.50

Group Chief Financial Officer recently bought kr130k worth of stock

What You Can Learn From Genovis AB (publ.)'s (STO:GENO) P/EAfter Its 25% Share Price Crash

We Think That There Are Issues Underlying Genovis AB (publ.)'s (STO:GENO) Earnings

Price target decreased by 7.5% to kr68.00

These Analysts Just Made A Huge Downgrade To Their Genovis AB (publ.) (STO:GENO) EPS Forecasts

Genovis AB (publ.) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 35%

Genovis AB (publ.), Annual General Meeting, May 15, 2024

New major risk - Revenue and earnings growth

Genovis AB (publ.) (STO:GENO) Analysts Are More Bearish Than They Used To Be

Price target decreased by 8.5% to kr73.50

Consensus revenue estimates fall by 13%

New major risk - Earnings quality

Third quarter 2023 earnings: EPS misses analyst expectations

New minor risk - Share price stability

Genovis AB (publ.) to Report First Half, 2024 Results on Aug 20, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 15%

Here's Why Genovis AB (publ.) (STO:GENO) Has Caught The Eye Of Investors

Genovis AB (publ.) to Report Q1, 2024 Results on May 15, 2024

Consensus EPS estimates increase by 22%

Director recently sold kr27m worth of stock

New major risk - Earnings quality

Are Genovis AB (publ.) (STO:GENO) Investors Paying Above The Intrinsic Value?

Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets

Consensus EPS estimates increase by 21%

What Does Genovis AB (publ.)'s (STO:GENO) Share Price Indicate?

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Chairman of the Board recently bought kr308k worth of stock

Independent Chairman of the Board recently bought kr308k worth of stock

Vice President of Sales & Marketing recently bought kr89k worth of stock

President & CEO recently bought kr118k worth of stock

Consensus EPS estimates increase by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 8.6% to kr76.00

Genovis AB (publ.) to Report Fiscal Year 2023 Results on Feb 15, 2024

Do Genovis AB (publ.)'s (STO:GENO) Earnings Warrant Your Attention?

Price target decreased to kr60.00

Third quarter 2022 earnings released: EPS: kr0.087 (vs kr0.013 in 3Q 2021)

Consensus forecasts updated

Genovis AB (publ.) to Report Nine Months, 2023 Results on Nov 15, 2023

Should You Think About Buying Genovis AB (publ.) (STO:GENO) Now?

Genovis AB (publ.) to Report Q1, 2023 Results on May 16, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind